John A Kanis1,2, Helena Johansson3, Nicholas C Harvey4,5, Eugene V McCloskey6,7. 1. Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK. w.j.pontefract@shef.ac.uk. 2. Mary McKillop Research Institute, Australian Catholic University, Melbourne, Australia. w.j.pontefract@shef.ac.uk. 3. Mary McKillop Research Institute, Australian Catholic University, Melbourne, Australia. 4. MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK. 5. NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK. 6. Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK. 7. Mellanby Centre for Bone Research, Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.
Abstract
This paper reviews the research programme that went into the development of FRAX® and its impact in the 10 years since its release in 2008. INTRODUCTION: Osteoporosis is defined on the measurement of bone mineral density though the clinical consequence is fracture. The sensitivity of bone mineral density measurements for fracture prediction is low, leading to the development of FRAX to better calculate the likelihood of fracture and target anti-osteoporosis treatments. METHODS: The method used in this paper is literature review. RESULTS: FRAX, developed over an 8-year period, was launched in 2008. Since the launch of FRAX, models have been made available for 64 countries and in 31 languages covering more than 80% of the world population. CONCLUSION: FRAX provides an advance in fracture risk assessment and a reference technology platform for future improvements in performance characteristics.
This paper reviews the research programme that went into the development of FRAX® and its impact in the 10 years since its release in 2008. INTRODUCTION:Osteoporosis is defined on the measurement of bone mineral density though the clinical consequence is fracture. The sensitivity of bone mineral density measurements for fracture prediction is low, leading to the development of FRAX to better calculate the likelihood of fracture and target anti-osteoporosis treatments. METHODS: The method used in this paper is literature review. RESULTS:FRAX, developed over an 8-year period, was launched in 2008. Since the launch of FRAX, models have been made available for 64 countries and in 31 languages covering more than 80% of the world population. CONCLUSION:FRAX provides an advance in fracture risk assessment and a reference technology platform for future improvements in performance characteristics.
Authors: John A Kanis; Eugene McCloskey; Helena Johansson; Anders Oden; William D Leslie Journal: Calcif Tissue Int Date: 2011-11-06 Impact factor: 4.333
Authors: O Johnell; J A Kanis; A Odén; I Sernbo; I Redlund-Johnell; C Petterson; C De Laet; B Jönsson Journal: Osteoporos Int Date: 2003-10-30 Impact factor: 4.507
Authors: John A Kanis; Olof Johnell; Dennis M Black; Robert W Downs; Somnath Sarkar; Thomas Fuerst; Roberta J Secrest; Imre Pavo Journal: Bone Date: 2003-09 Impact factor: 4.398
Authors: Nicholas R Fuggle; Elizabeth M Curtis; Kate A Ward; Nicholas C Harvey; Elaine M Dennison; Cyrus Cooper Journal: Nat Rev Endocrinol Date: 2019-09 Impact factor: 43.330
Authors: M Chandran; P J Mitchell; T Amphansap; S K Bhadada; M Chadha; D-C Chan; Y-S Chung; P Ebeling; N Gilchrist; A Habib Khan; P Halbout; F L Hew; H-P T Lan; T C Lau; J K Lee; S Lekamwasam; G Lyubomirsky; L B Mercado-Asis; A Mithal; T V Nguyen; D Pandey; I R Reid; A Suzuki; T T Chit; K L Tiu; T Valleenukul; C K Yung; Y L Zhao Journal: Osteoporos Int Date: 2021-01-27 Impact factor: 4.507
Authors: M Kebaetse; S Nkhwa; M Mogodi; J Masunge; Y P Gureja; M Ramabu; T Mmopelwa; I Sharif; A Orford; N C Harvey; E V McCloskey; J A Cauley; J A Kanis; H Johansson Journal: Arch Osteoporos Date: 2021-06-07 Impact factor: 2.617